FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136339875> ?p ?o ?g. }

• W3136339875 endingPage "466" @default.
• W3136339875 startingPage "463" @default.
• W3136339875 abstract "Late-onset neutropaenia is defined as an absolute neutrophil count of <1.5 × 103 cells/μL starting > 4 weeks after the last dose of rituximab, in the absence of other identifiable causes. Late-onset neutropaenia is a rare adverse reaction to rituximab (observed in approximately 5% of patients). Rheumatic diseases constitute the main indication for rituximab; in these patients, neutropaenia appears after a mean of > 28 days. Ocrelizumab is another monoclonal antibody that binds to CD20 (a glycosylated phosphoprotein mainly expressed on the membranes of B-lymphocytes); in January 2018, it was approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis. We present a case of neutropaenia following intravenous infusion of ocrelizumab in a patient with primary progressive multiple sclerosis who presented with neutropaenic fever, herpetic stomatitis, and ecthyma gangrenosum only 20 days after infusion. La neutropenia de aparición tardía se define como un recuento absoluto de neutrófilos < 1,5 × 103/μl que se produce > 4 semanas después de la última dosis de rituximab, precedido por un recuento de neutrófilos normal y sin otra causa identificable. Es una complicación rara del tratamiento con rituximab, habiéndose observado en aproximadamente el 5% de los pacientes tratados, siendo las enfermedades reumáticas su principal indicación, con un tiempo medio hasta el desarrollo de la neutropenia de al menos 28 días. El ocrelizumab, al igual que el rituximab, es un anticuerpo monoclonal dirigido a CD20, una fosfoproteína glicosilada de membrana que se encuentra predominantemente en los linfocitos B y que se aprobó en enero de 2018 para el tratamiento de la esclerosis múltiple remitente recurrente y la esclerosis múltiple progresiva primaria. Se describe un caso de neutropenia después de la infusión de ocrelizumab en un paciente con esclerosis múltiple progresiva primaria que presentó neutropenia febril, estomatitis herpética y ectima gangrenoso solo 20 días después de la infusión." @default.
• W3136339875 created "2021-03-29" @default.
• W3136339875 creator A5002785242 @default.
• W3136339875 creator A5039474768 @default.
• W3136339875 creator A5042781346 @default.
• W3136339875 creator A5064701528 @default.
• W3136339875 creator A5071694110 @default.
• W3136339875 date "2023-09-01" @default.
• W3136339875 modified "2023-10-01" @default.
• W3136339875 title "Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab" @default.
• W3136339875 cites W2011044675 @default.
• W3136339875 cites W2045269975 @default.
• W3136339875 cites W2058416888 @default.
• W3136339875 cites W2096128064 @default.
• W3136339875 cites W2126169144 @default.
• W3136339875 cites W2399591450 @default.
• W3136339875 cites W2771633521 @default.
• W3136339875 cites W2909549156 @default.
• W3136339875 cites W3025861682 @default.
• W3136339875 doi "https://doi.org/10.1016/j.nrl.2021.01.010" @default.
• W3136339875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33726971" @default.
• W3136339875 hasPublicationYear "2023" @default.
• W3136339875 type Work @default.
• W3136339875 sameAs 3136339875 @default.
• W3136339875 citedByCount "1" @default.
• W3136339875 countsByYear W31363398752022 @default.
• W3136339875 crossrefType "journal-article" @default.
• W3136339875 hasAuthorship W3136339875A5002785242 @default.
• W3136339875 hasAuthorship W3136339875A5039474768 @default.
• W3136339875 hasAuthorship W3136339875A5042781346 @default.
• W3136339875 hasAuthorship W3136339875A5064701528 @default.
• W3136339875 hasAuthorship W3136339875A5071694110 @default.
• W3136339875 hasBestOaLocation W31363398751 @default.
• W3136339875 hasConcept C126322002 @default.
• W3136339875 hasConcept C159654299 @default.
• W3136339875 hasConcept C18031839 @default.
• W3136339875 hasConcept C203014093 @default.
• W3136339875 hasConcept C2776694085 @default.
• W3136339875 hasConcept C2777063308 @default.
• W3136339875 hasConcept C2778843634 @default.
• W3136339875 hasConcept C2779171977 @default.
• W3136339875 hasConcept C2780640218 @default.
• W3136339875 hasConcept C2780653079 @default.
• W3136339875 hasConcept C71924100 @default.
• W3136339875 hasConceptScore W3136339875C126322002 @default.
• W3136339875 hasConceptScore W3136339875C159654299 @default.
• W3136339875 hasConceptScore W3136339875C18031839 @default.
• W3136339875 hasConceptScore W3136339875C203014093 @default.
• W3136339875 hasConceptScore W3136339875C2776694085 @default.
• W3136339875 hasConceptScore W3136339875C2777063308 @default.
• W3136339875 hasConceptScore W3136339875C2778843634 @default.
• W3136339875 hasConceptScore W3136339875C2779171977 @default.
• W3136339875 hasConceptScore W3136339875C2780640218 @default.
• W3136339875 hasConceptScore W3136339875C2780653079 @default.
• W3136339875 hasConceptScore W3136339875C71924100 @default.
• W3136339875 hasIssue "7" @default.
• W3136339875 hasLocation W31363398751 @default.
• W3136339875 hasOpenAccess W3136339875 @default.
• W3136339875 hasPrimaryLocation W31363398751 @default.
• W3136339875 hasRelatedWork W2272446420 @default.
• W3136339875 hasRelatedWork W2511874056 @default.
• W3136339875 hasRelatedWork W2768964978 @default.
• W3136339875 hasRelatedWork W2809611711 @default.
• W3136339875 hasRelatedWork W2884204030 @default.
• W3136339875 hasRelatedWork W3025861682 @default.
• W3136339875 hasRelatedWork W3136339875 @default.
• W3136339875 hasRelatedWork W3206160011 @default.
• W3136339875 hasRelatedWork W4285384838 @default.
• W3136339875 hasRelatedWork W4312925133 @default.
• W3136339875 hasVolume "38" @default.
• W3136339875 isParatext "false" @default.
• W3136339875 isRetracted "false" @default.
• W3136339875 magId "3136339875" @default.
• W3136339875 workType "article" @default.